RU2019100221A - Составы на основе антитела к CD19 - Google Patents
Составы на основе антитела к CD19 Download PDFInfo
- Publication number
- RU2019100221A RU2019100221A RU2019100221A RU2019100221A RU2019100221A RU 2019100221 A RU2019100221 A RU 2019100221A RU 2019100221 A RU2019100221 A RU 2019100221A RU 2019100221 A RU2019100221 A RU 2019100221A RU 2019100221 A RU2019100221 A RU 2019100221A
- Authority
- RU
- Russia
- Prior art keywords
- concentration
- composition
- paragraphs
- composition according
- antibody
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 25
- 238000009472 formulation Methods 0.000 title claims 4
- 239000007979 citrate buffer Substances 0.000 claims 5
- 229920000136 polysorbate Polymers 0.000 claims 5
- 229950008882 polysorbate Drugs 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 3
- 229930006000 Sucrose Natural products 0.000 claims 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- 239000008363 phosphate buffer Substances 0.000 claims 3
- 239000005720 sucrose Substances 0.000 claims 3
- 239000000872 buffer Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Claims (19)
1. Стабильный лиофилизированный фармацевтический состав, при этом состав содержит антитело к CD19 в концентрации, составляющей от 20 мг/мл до 125 мг/мл, буфер, полисорбат в концентрации, составляющей от 0,005% (вес/об.) до 0,06% (вес/об.), и с показателем рН, составляющим 6,0, где состав дополнительно содержит
a) трегалозу в концентрации, составляющей от 180 мМ до 240 мМ, или
b) маннит в концентрации, составляющей от 180 мМ до 240 мМ, и сахарозу в концентрации, составляющей от 10 мМ до 50 мМ,
и где указанное антитело к CD19 содержит константный домен тяжелой цепи с последовательностью
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSWTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRWSVLTWHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 8) и константный домен легкой цепи с последовательностью RTVAAPSVFIFPPSDEQLKSGTASWCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 9).
2. Состав по п. 1, где концентрация указанного антитела к CD19 в составе составляет 40 мг/мл.
3. Состав по любому из п. 1 или 2, где указанный буфер представляет собой цитратный буфер или фосфатный буфер.
4. Состав по п. 3, где концентрация указанного цитратного буфера или фосфатного буфера составляет от 20 до 50 мМ.
5. Состав по п. 4, где концентрация указанного цитратного буфера или фосфатного буфера составляет 25 мМ.
6. Состав по любому из пп. 1-5, где концентрация указанной трегалозы в составе составляет 200 мМ.
7. Состав по любому из пп. 1-5, где концентрация указанного маннита в составе составляет 219 мМ, и концентрация указанной сахарозы в составе составляет 29 мМ.
8. Состав по любому из пп. 1-7, где указанный полисорбат в составе представляет собой полисорбат 20.
9. Состав по любому из пп. 1-8, где концентрация указанного полисорбата в составе составляет 0,02%.
10. Состав по любому из пп. 1-9, где указанное антитело к CD19 представляет собой антитело lgG1, lgG2, lgG3 или lgG4.
11. Состав по любому из пп. 1-10, где состав является стабильным при 2-8°С в течение по меньшей мере 6 месяцев, по меньшей мере 12 месяцев, по меньшей мере 18 месяцев, по меньшей мере 24 месяцев или по меньшей мере 36 месяцев.
12. Состав по любому из пп. 1-5, где количество указанного антитела к CD19 составляет 40 мг/мл, концентрация указанного цитратного буфера составляет 25 мМ, концентрация указанной трегалозы составляет 200 мМ, концентрация полисорбата составляет 0,02% (вес/об.), и указанный состав характеризуется показателем рН, составляющим 6,0.
13. Состав по любому из пп. 1-5, где количество указанного антитела к CD19 составляет 40 мг/мл, концентрация указанного цитратного буфера составляет 25 мМ, концентрация указанного маннита составляет 219 мМ, и концентрация указанной сахарозы составляет 29 мМ, концентрация полисорбата составляет 0,02% (вес/об.), и указанный состав характеризуется показателем рН, составляющим 6,0.
14. Изделие, содержащее контейнер, в котором содержится стабильный лиофилизированный фармацевтический состав по любому из пп. 1-13.
15. Способ лечения заболевания или нарушения у субъекта, включающий введение субъекту эффективного количества состава по любому из пп. 1-13, где заболевание или нарушение представляет собой рак.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16176322.2 | 2016-06-27 | ||
| EP16176322 | 2016-06-27 | ||
| PCT/EP2017/065819 WO2018002031A1 (en) | 2016-06-27 | 2017-06-27 | Anti-cd19 antibody formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019100221A true RU2019100221A (ru) | 2020-07-28 |
| RU2019100221A3 RU2019100221A3 (ru) | 2020-11-30 |
| RU2748024C2 RU2748024C2 (ru) | 2021-05-19 |
Family
ID=56368805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019100221A RU2748024C2 (ru) | 2016-06-27 | 2017-06-27 | Составы на основе антитела к CD19 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11352423B2 (ru) |
| EP (2) | EP3475303B1 (ru) |
| JP (3) | JP2019524671A (ru) |
| KR (2) | KR20230074823A (ru) |
| CN (2) | CN115998859A (ru) |
| AU (2) | AU2017289085B2 (ru) |
| CA (1) | CA3029137A1 (ru) |
| CY (1) | CY1124521T1 (ru) |
| DK (1) | DK3475303T3 (ru) |
| ES (1) | ES2874640T3 (ru) |
| HR (1) | HRP20210945T1 (ru) |
| HU (1) | HUE054296T2 (ru) |
| IL (1) | IL263764B2 (ru) |
| LT (1) | LT3475303T (ru) |
| MA (1) | MA45450B1 (ru) |
| MD (1) | MD3475303T2 (ru) |
| MX (1) | MX2018016362A (ru) |
| PL (1) | PL3475303T3 (ru) |
| PT (1) | PT3475303T (ru) |
| RS (1) | RS62035B1 (ru) |
| RU (1) | RU2748024C2 (ru) |
| SG (2) | SG11201810429UA (ru) |
| SI (1) | SI3475303T1 (ru) |
| WO (1) | WO2018002031A1 (ru) |
| ZA (1) | ZA201900483B (ru) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021015034A2 (pt) | 2019-02-18 | 2021-10-05 | Eli Lilly And Company | Formulação de anticorpo terapêutico |
| JP2022550435A (ja) | 2019-10-04 | 2022-12-01 | ウルトラジェニックス ファーマシューティカル インコーポレイテッド | 組換えａａｖの改善された治療的使用のための方法 |
| EP4051710A1 (en) | 2019-10-31 | 2022-09-07 | MorphoSys AG | Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells |
| JP2023530499A (ja) | 2020-06-22 | 2023-07-18 | モルフォシス・アーゲー | 抗ＣＤ１９抗体及びＳＩＲＰα－ＣＤ４７自然免疫チェックポイントを遮断するポリペプチドを含む抗腫瘍組み合わせ療法 |
| EP4225792A1 (en) | 2020-10-08 | 2023-08-16 | Affimed GmbH | Trispecific binders |
| WO2023007023A1 (en) | 2021-07-30 | 2023-02-02 | Affimed Gmbh | Duplexbodies |
| WO2023073645A1 (en) | 2021-10-29 | 2023-05-04 | Takeda Pharmaceutical Company Limited | Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor |
| KR20240099382A (ko) | 2021-11-03 | 2024-06-28 | 아피메트 게엠베하 | 이중특이적 cd16a 결합제 |
| WO2023215674A1 (en) * | 2022-05-03 | 2023-11-09 | Xencor, Inc. | Methods for treating lymphoma |
| WO2024038115A1 (en) | 2022-08-17 | 2024-02-22 | Morphosys Ag | Therapy comprising anti-cd19 antibody and ezh2 modulators |
| WO2024180511A1 (en) * | 2023-03-02 | 2024-09-06 | Novetide Ltd. | Process for preparation of glp-1 peptides having controlled particle size |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| CA2534639C (en) | 2003-07-31 | 2013-07-30 | Immunomedics, Inc. | Anti-cd19 antibodies |
| EP1899379B1 (en) | 2005-06-20 | 2018-04-11 | E. R. Squibb & Sons, L.L.C. | Cd19 antibodies and their uses |
| EP2270050B1 (en) | 2005-12-30 | 2013-06-05 | Merck Patent GmbH | Anti-CD19 antibodies with reduced immunogenicity |
| ES2402591T3 (es) * | 2006-08-14 | 2013-05-07 | Xencor Inc. | Anticuerpos optimizados que seleccionan como diana CD19 |
| EP2066349B1 (en) | 2006-09-08 | 2012-03-28 | MedImmune, LLC | Humanized anti-cd19 antibodies and their use in treatment of tumors, transplantation and autoimmune diseases |
| EP2708557A1 (en) | 2007-05-30 | 2014-03-19 | Xencor, Inc. | Method and compositions for inhibiting CD32B expressing cells |
| CN101874042B9 (zh) * | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| LT2211904T (lt) | 2007-10-19 | 2016-11-25 | Seattle Genetics, Inc. | Cd19 surišantys agentai ir jų panaudojimas |
| US8679492B2 (en) | 2009-02-23 | 2014-03-25 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to CD19 and their uses |
| CN102413839A (zh) * | 2009-03-06 | 2012-04-11 | 医学免疫有限责任公司 | 人源化抗cd19抗体制剂 |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| AU2014243783B2 (en) | 2013-03-13 | 2018-12-13 | Genentech, Inc. | Antibody formulations |
| JP6389236B2 (ja) | 2013-03-13 | 2018-09-12 | ジェネンテック， インコーポレイテッド | 酸化還元製剤 |
| US10513555B2 (en) * | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| EA201991715A1 (ru) | 2013-09-27 | 2020-03-31 | Дженентек, Инк. | Композиции, содержащие антитело к pdl1 |
| WO2015075201A1 (en) | 2013-11-21 | 2015-05-28 | Genmab A/S | Antibody-drug conjugate lyophilised formulation |
| CN106132434A (zh) * | 2014-04-07 | 2016-11-16 | 西雅图基因公司 | 抗‑cd19抗体和抗体‑药物偶联物的稳定制剂 |
-
2017
- 2017-06-27 DK DK17735440.4T patent/DK3475303T3/da active
- 2017-06-27 CN CN202211458395.0A patent/CN115998859A/zh active Pending
- 2017-06-27 MD MDE20190533T patent/MD3475303T2/ro unknown
- 2017-06-27 SI SI201730801T patent/SI3475303T1/sl unknown
- 2017-06-27 KR KR1020237016157A patent/KR20230074823A/ko not_active Application Discontinuation
- 2017-06-27 CA CA3029137A patent/CA3029137A1/en active Pending
- 2017-06-27 PL PL17735440T patent/PL3475303T3/pl unknown
- 2017-06-27 RS RS20210748A patent/RS62035B1/sr unknown
- 2017-06-27 LT LTEP17735440.4T patent/LT3475303T/lt unknown
- 2017-06-27 CN CN201780039737.6A patent/CN109415440B/zh active Active
- 2017-06-27 SG SG11201810429UA patent/SG11201810429UA/en unknown
- 2017-06-27 WO PCT/EP2017/065819 patent/WO2018002031A1/en unknown
- 2017-06-27 AU AU2017289085A patent/AU2017289085B2/en active Active
- 2017-06-27 KR KR1020197002043A patent/KR102533875B1/ko active IP Right Grant
- 2017-06-27 PT PT177354404T patent/PT3475303T/pt unknown
- 2017-06-27 IL IL263764A patent/IL263764B2/en unknown
- 2017-06-27 MX MX2018016362A patent/MX2018016362A/es unknown
- 2017-06-27 RU RU2019100221A patent/RU2748024C2/ru active
- 2017-06-27 HU HUE17735440A patent/HUE054296T2/hu unknown
- 2017-06-27 SG SG10201912369QA patent/SG10201912369QA/en unknown
- 2017-06-27 EP EP17735440.4A patent/EP3475303B1/en active Active
- 2017-06-27 JP JP2018567742A patent/JP2019524671A/ja active Pending
- 2017-06-27 EP EP21167818.0A patent/EP3909985A1/en active Pending
- 2017-06-27 ES ES17735440T patent/ES2874640T3/es active Active
- 2017-06-27 MA MA45450A patent/MA45450B1/fr unknown
- 2017-06-27 US US16/310,555 patent/US11352423B2/en active Active
-
2019
- 2019-01-23 ZA ZA2019/00483A patent/ZA201900483B/en unknown
-
2021
- 2021-06-14 HR HRP20210945TT patent/HRP20210945T1/hr unknown
- 2021-06-14 CY CY20211100532T patent/CY1124521T1/el unknown
-
2022
- 2022-03-22 US US17/700,809 patent/US20220213190A1/en active Pending
- 2022-05-18 JP JP2022081779A patent/JP2022119854A/ja active Pending
-
2024
- 2024-05-23 JP JP2024083988A patent/JP2024109816A/ja active Pending
- 2024-07-24 AU AU2024205042A patent/AU2024205042A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019100221A (ru) | Составы на основе антитела к CD19 | |
| AR124676A2 (es) | Formulación farmacéutica que comprende una droga biofarmacéutica | |
| HRP20192285T1 (hr) | Anti-ox40 protutijela i postupci uporabe | |
| PE20200513A1 (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso | |
| PE20091327A1 (es) | Composicion farmaceutica que comprende anticuerpos monoclonales | |
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| RU2018140960A (ru) | Композиции, содержащие комбинированный состав на основе антител к pd-l1 и ctla-4 | |
| RU2015143607A (ru) | Составы антител | |
| NZ730821A (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
| NZ719036A (en) | Anti-pdl1 antibody formulations | |
| JP2022119854A5 (ru) | ||
| HRP20120903T1 (hr) | Tekuä†a formulacija koja sadrži visoku koncentraciju protutijela | |
| PE20141413A1 (es) | Formulaciones de anticuerpo y metodos | |
| RU2019100887A (ru) | Композиции антитела и белка | |
| PE20211453A1 (es) | Formulacion liofilizada de un anticuerpo monoclonal contra transtirretina | |
| SI2691112T1 (en) | STABILITY FORMULATION PROTITELES FOR HUMAN PROGRAMMED DEPRESSOR RECEPTOR PD-1 AND RELATED HEALTH | |
| NZ705178A (en) | Anti-prolactin receptor antibody formulations | |
| JP2016533335A5 (ru) | ||
| PE20060879A1 (es) | Formulacion anticuerpo anti a beta | |
| DE602006017965D1 (de) | Maleimid-derivate, pharmazeutische zusammensetzungen und verfahren zur behandlung von krebs | |
| EA200701519A1 (ru) | Живая аттенуированная ротавирусная вакцина для перорального введения | |
| RU2021137159A (ru) | Стабильные водные составы на основе антител | |
| PE20121687A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r) | |
| HRP20110334T1 (hr) | PROTUTIJELA SPECIFIČNA ZA TGF-ß1 | |
| JP2019514998A5 (ru) |